An ALBI- and Ascites-Based Model to Predict Survival for BCLC Stage B Hepatocellular Carcinoma

Table 3

The comparison of the ALBI-AS based model versus other models for BCLC stage B HCC patients.

Model	1-yr AUROC	2-yr AUROC	3-yr AUROC	C-index (95% CI)	AIC
Training group
The present model	0.73	0.69	0.67	0.68 (0.66–0.70)	6216.3
Up-to-seven	0.62	0.63	0.62	0.59 (0.57–0.61)	6290.2
Four-and-seven	0.65	0.63	0.62	0.62 (0.60–0.64)	6298.8
Six-and-twelve	0.66	0.64	0.62	0.63 (0.61–0.65)	5449.1
BCLC-B substaging system	0.60	0.59	0.59	0.59 (0.57–0.61)	6308.9
New BCLC-B substaging system	0.61	0.60	0.59	0.59 (0.57–0.62)	6320.8
HAP	0.60	0.59	0.58	0.58 (0.56–0.61)	6351.1
mHAP II	0.56	0.56	0.55	0.55 (0.53–0.57)	6357.3
ALBI-TAE model	0.67	0.65	0.64	0.64 (0.62–0.67)	6283.5
Internal validation group
The present model	0.72	0.71	0.69	0.70 (0.67–0.74)	2306.2
Up-to-seven	0.62	0.61	0.60	0.61 (0.59–0.63)	2335.4
Four-and-seven	0.65	0.63	0.61	0.63 (0.59–0.66)	2356.8
Six-and-twelve	0.64	0.64	0.63	0.63 (0.60–0.66)	2339.3
BCLC-B substaging system	0.64	0.63	0.62	0.63 (0.59–0.66)	2336.1
New BCLC-B substaging system	0.65	0.63	0.62	0.64 (0.60–0.67)	2346.5
HAP	0.61	0.61	0.59	0.60 (0.56–0.63)	2376.8
mHAP II	0.57	0.58	0.56	0.57 (0.54–0.60)	2381.4
ALBI-TAE model	0.69	0.67	0.65	0.67 (0.63–0.70)	2334.7
External validation group
The present model	0.71	0.70	0.68	0.67 (0.64–0.71)	2056.6
Up-to-seven	0.61	0.60	0.59	0.59 (0.56–0.61)	2090.2
Four-and-seven	0.68	0.66	0.65	0.65 (0.62–0.68)	2074.3
Six-and-twelve	0.67	0.65	0.63	0.63 (0.60–0.66)	2082.8
BCLC-B substaging system	0.63	0.61	0.60	0.61 (0.57–0.63)	2091.1
New BCLC-B substaging system	0.66	0.64	0.63	0.63 (0.59–0.66)	2078.7
HAP	0.60	0.59	0.59	0.59 (0.54–0.62)	2107.3
mHAP II	0.57	0.57	0.56	0.56 (0.23–0.59)	2106.7
ALBI-TAE model	0.67	0.66	0.65	0.64 (0.60–0.68)	2081.9

AUROC, area under the receiver operating characteristics curves; CI, confidence interval; AIC, akaike information criterion.